Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip S Bernard

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Clinical Chemistry|July 27, 2002
Real-time PCR technology for cancer diagnosticsPhilip S Bernard, Carl T Wittwer
Clinical Biochemistry|July 6, 2004
State of the science: molecular classifications of breast cancer for clinical diagnosticsJohn E Robison, Laurent Perreard, Philip S Bernard
Journal of Surgical Oncology|July 29, 2003
Color multiplex polymerase chain reaction for quantitative analysis of epidermal growth factor receptor genes in colorectal adenocarcinomaLester J Layfield, Philip S Bernard, Neil S Goldstein
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 6, 2007
Differentiating Ewing's sarcoma from other round blue cell tumors using a RT-PCR translocation panel on formalin-fixed paraffin-embedded tissuesTracey B Lewis, Cheryl M Coffin, Philip S Bernard
Nature Genetics|November 28, 2002
Molecular portraits and the family tree of cancerChristine H Chung, Philip S Bernard, Charles M Perou
Clinical Chemistry|July 27, 2002
Homogeneous amplification and mutation scanning of the p53 gene using fluorescent melting curvesHaleigh Millward, Wade Samowitz, Carl T Wittwer, et al.
BMC Research Notes|May 28, 2011
High quality and quantity Genome-wide germline genotypes from FFPE normal tissueLisa A Cannon-Albright, Kendal G Cooper, Ann Georgelas, et al.
The American Journal of Pathology|December 6, 2011
TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancerJin Liu, Bryan Welm, Ken M Boucher, et al.
Plos One|December 24, 2019
Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemiaKibum Kim, Gwendolyn A McMillin, Philip S Bernard, et al.
Medrxiv : the Preprint Server for Health Sciences|July 10, 2026
The MHCII Immune Activation Score predicts risk of recurrence and benefit of taxanes in Basal-like and HER2-enriched breast cancerPhilip S Bernard, Bingshu E Chen, Dongxia Gao, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Clinical Chemistry|July 27, 2002
Real-time PCR technology for cancer diagnosticsPhilip S Bernard, Carl T Wittwer
Clinical Biochemistry|July 6, 2004
State of the science: molecular classifications of breast cancer for clinical diagnosticsJohn E Robison, Laurent Perreard, Philip S Bernard
Journal of Surgical Oncology|July 29, 2003
Color multiplex polymerase chain reaction for quantitative analysis of epidermal growth factor receptor genes in colorectal adenocarcinomaLester J Layfield, Philip S Bernard, Neil S Goldstein
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 6, 2007
Differentiating Ewing's sarcoma from other round blue cell tumors using a RT-PCR translocation panel on formalin-fixed paraffin-embedded tissuesTracey B Lewis, Cheryl M Coffin, Philip S Bernard
Nature Genetics|November 28, 2002
Molecular portraits and the family tree of cancerChristine H Chung, Philip S Bernard, Charles M Perou
Clinical Chemistry|July 27, 2002
Homogeneous amplification and mutation scanning of the p53 gene using fluorescent melting curvesHaleigh Millward, Wade Samowitz, Carl T Wittwer, et al.
BMC Research Notes|May 28, 2011
High quality and quantity Genome-wide germline genotypes from FFPE normal tissueLisa A Cannon-Albright, Kendal G Cooper, Ann Georgelas, et al.
The American Journal of Pathology|December 6, 2011
TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancerJin Liu, Bryan Welm, Ken M Boucher, et al.
Plos One|December 24, 2019
Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemiaKibum Kim, Gwendolyn A McMillin, Philip S Bernard, et al.
Medrxiv : the Preprint Server for Health Sciences|July 10, 2026
The MHCII Immune Activation Score predicts risk of recurrence and benefit of taxanes in Basal-like and HER2-enriched breast cancerPhilip S Bernard, Bingshu E Chen, Dongxia Gao, et al.
Pageof 7